State of Alaska Department of Revenue Has $16.66 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

State of Alaska Department of Revenue cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 180,407 shares of the biopharmaceutical company’s stock after selling 25,164 shares during the period. State of Alaska Department of Revenue’s holdings in Gilead Sciences were worth $16,663,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. HHM Wealth Advisors LLC increased its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter worth about $29,000. Finally, Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $99.65 on Thursday. The stock has a market cap of $124.19 billion, a price-to-earnings ratio of 1,107.22, a P/E/G ratio of 1.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a 50 day simple moving average of $92.71 and a 200 day simple moving average of $86.32. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 in the last 90 days. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. BMO Capital Markets lifted their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. UBS Group increased their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Truist Financial lifted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Mizuho increased their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Finally, Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.